^
    9d
    Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer (clinicaltrials.gov)
    P3, N=874, Not yet recruiting, Shanghai Shengdi Pharmaceutical Co., Ltd
    New P3 trial
    |
    oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • AiRuiLi (adebrelimab)
    15d
    A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer (clinicaltrials.gov)
    P2, N=63, Recruiting, Asan Medical Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Jun 2025 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    docetaxel • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    15d
    A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression (clinicaltrials.gov)
    P2, N=37, Active, not recruiting, Yongxu Jia | Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2025 --> Jun 2026
    Enrollment closed • Trial primary completion date • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 negative
    |
    Focus V (anlotinib) • oxaliplatin • Andewei (benmelstobart) • Teysuno (gimeracil/oteracil/tegafur)
    15d
    Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P2, N=46, Not yet recruiting, Fudan University
    New P2 trial
    |
    AFP (Alpha-fetoprotein)
    |
    Avastin (bevacizumab) • Tyvyt (sintilimab) • capecitabine • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    15d
    Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P2, N=68, Completed, Asan Medical Center | Recruiting --> Completed
    Trial completion • pMMR
    |
    MSI (Microsatellite instability)
    |
    Imfinzi (durvalumab) • docetaxel • Imjudo (tremelimumab-actl) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    17d
    Solitary adrenal metastatic adenocarcinoma one year after radical gastrectomy for gastric cancer: a case report. (PubMed, Front Med (Lausanne))
    The patient completed six cycles of adjuvant chemotherapy with tegafur-gimeracil-oteracil (S-1) plus oxaliplatin, and routine follow-up examinations showed no evidence of recurrence...The patient was treated with SOX chemotherapy combined with the PD-1 inhibitor tislelizumab...This case highlights the importance of vigilance for rare metastatic sites, such as the adrenal gland, in patients with advanced gastric cancer even after standardized postoperative surveillance. Systemic chemotherapy combined with immunotherapy may represent an effective treatment strategy for selected patients with metastatic gastric cancer.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • CA 19-9 (Cancer antigen 19-9)
    |
    Tevimbra (tislelizumab-jsgr) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    20d
    Pembrolizumab plus chemotherapy following lack of response to nivolumab-based therapy in MSI-High/dMMR advanced gastric cancer: a case report. (PubMed, Int Cancer Conf J)
    He subsequently received ramucirumab-based therapy, paclitaxel, and irinotecan...Pembrolizumab combined with capecitabine and oxaliplatin (CAPOX) was initiated as fifth-line therapy, resulting in notable regression of hepatic and nodal metastases. This case underscores the clinical importance of early MSI/MMR and genomic testing and suggests that re-administration of ICI plus chemotherapy may be a therapeutic option for selected patients with advanced gastric cancer who initially show limited response to ICI-based therapy.
    Journal • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker • MSI-H • dMMR
    |
    HER-2 (Human epidermal growth factor receptor 2) • MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • PMS2 (PMS1 protein homolog 2)
    |
    MSI-H/dMMR • HER-2 negative
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • paclitaxel • capecitabine • Cyramza (ramucirumab) • oxaliplatin • irinotecan • Teysuno (gimeracil/oteracil/tegafur)
    21d
    Adjuvant Pembrolizumab in patients with early-stage triple negative breast cancer with residual disease after treatment with chemotherapy and pembrolizumab (2025-524229-41-00)
    P2/3, N=1000, Not yet recruiting, Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
    New P2/3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • HER-2 expression
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib) • capecitabine • Teysuno (gimeracil/oteracil/tegafur)
    22d
    Metastatic Breast Cancer Presenting as an Organizing Pneumonia Pattern on Chest CT: A Case Report. (PubMed, Cureus)
    The patient had been receiving fulvestrant for known pulmonary metastasis diagnosed 14 years prior...Treatment with S-1 resulted in radiological improvement at four months. This case adds to the limited literature documenting OP-mimicking pulmonary metastasis from breast cancer and highlights the importance of maintaining a high index of suspicion and pursuing tissue diagnosis in patients with a history of breast cancer who present with new pulmonary infiltrates.
    Journal
    |
    ER (Estrogen receptor) • GATA3 (GATA binding protein 3)
    |
    fulvestrant • Teysuno (gimeracil/oteracil/tegafur)
    22d
    Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhibitors for Pancreatic Cancer Liver Metastases (clinicaltrials.gov)
    P2, N=50, Recruiting, Ruijin Hospital
    New P2 trial
    |
    Tyvyt (sintilimab) • Tevimbra (tislelizumab-jsgr) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    28d
    Gemcitabine/nab-paclitaxel plus S-1 combination compared with gemcitabine/nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: a retrospective study. (PubMed, Ther Adv Med Oncol)
    No treatment-related mortality was found. The S-1 could be combined with GA as another potential triplet combination treatment option for advanced PDAC.
    Retrospective data • Journal
    |
    FoundationOne® CDx
    |
    gemcitabine • albumin-bound paclitaxel • Teysuno (gimeracil/oteracil/tegafur)
    28d
    TOURMALINE: Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) (clinicaltrials.gov)
    P3, N=142, Active, not recruiting, AstraZeneca | Trial completion date: Mar 2026 --> Sep 2026
    Trial completion date
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)